Streetbeat News

Price Targets

JAZZ

RBC Capital analyst Gregory Renza has maintained an 'Outperform' rating on Jazz Pharmaceuticals and slightly raised the price target from $174 to $175.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 3:52 pm

LUMN

Goldman Sachs analyst James Schneider maintains a Neutral rating on Lumen Technologies (NYSE:LUMN) and raises the price target from $4 to $4.5.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 3:52 pm

CCOI

Goldman Sachs analyst James Schneider maintains a Neutral rating on Cogent Comms Hldgs (NASDAQ:CCOI) but raises the price target from $62 to $71.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 3:50 pm

V

Financial giants are making bullish moves on Visa options, with a significant portion of trades being puts and calls. Analysts have set price targets for Visa between $240 and $315, with a consensus target of $310.6. Visa's current market position is stable, with a slight price increase and neutral RSI readings.

Portfolio Pulse from Benzinga Insights

October 04, 2024 | 3:46 pm

INO

RBC Capital analyst Gregory Renza has maintained a Sector Perform rating on Inovio Pharmaceuticals but has lowered the price target from $8 to $7.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 3:45 pm

EXEL

RBC Capital analyst Gregory Renza maintains an Outperform rating on Exelixis (NASDAQ:EXEL) and raises the price target from $27 to $30.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 3:40 pm

WVE

RBC Capital analyst Luca Issi maintains a Sector Perform rating on WAVE Life Sciences (NASDAQ:WVE) and raises the price target from $5 to $7.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 3:38 pm

AEP

BMO Capital analyst James Thalacker maintains an Outperform rating on American Electric Power (NASDAQ:AEP) but lowers the price target from $114 to $111.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 3:37 pm

CRSP

RBC Capital analyst Luca Issi maintains a Sector Perform rating on CRISPR Therapeutics but lowers the price target from $60 to $53.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 3:35 pm

VST

BMO Capital has reiterated its Outperform rating on Vistra and increased the price target from $125 to $146, indicating confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 3:35 pm